Doxorubicin and Edelfosine Combo-Loaded Lipid-Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction] [0.03%]
多柔比星和édelfosine联合加载的脂质聚合物混合型纳米颗粒对耐药性骨肉瘤的协同抗癌效果[撤稿]
[This retracts the article DOI: 10.2147/OTT.S259428.]. © 2026 Dove Medical Press.
Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma: A Single-Center Case Series of Five Patients [0.03%]
弥漫硬化型乳头状甲状腺癌五例报告
XiaoYu Sun,Yanze Liu,Jie Peng et al.
XiaoYu Sun et al.
Background: Diffuse sclerosing variant papillary thyroid carcinoma (DSVPTC) is a rare subtype of papillary thyroid carcinoma characterized by diffuse intrathyroidal involvement and frequent cervical lymph node metastasis....
A Novel Strategy for Treating Elderly Patients with Advanced Non-Small Cell Lung Cancer: Exploring the Efficacy and Safety of Anlotinib Combined with PD-1/PD-L1 Inhibitors [0.03%]
老年晚期非小细胞肺癌患者治疗新策略——探索安罗替尼联合PD-1/PD-L1抑制剂的疗效及安全性
Chuanzhen Chi,Li Li,Chunhua Xu
Chuanzhen Chi
Objective: This study aimed to explore whether the combination of anlotinib and immunotherapy is an effective and safe alternative to chemotherapy for clinical treatment. Provide a new treatment plan for elderly patients ...
High-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Real-World Retrospective Experience from Two Tertiary Centers [0.03%]
晚期小细胞肺癌的高剂量每日两次胸部放疗：来自两家三级中心的真实世界回顾性经验
Oded Icht,Bilal Krayim,Mor Moskovitz et al.
Oded Icht et al.
Background: Hyperfractionated thoracic radiotherapy (RT) is a standard component of curative treatment for limited-stage small-cell lung cancer (LS-SCLC). While 45 Gy in 30 twice-daily fractions remains the most validated...
Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation [0.03%]
弥漫性大B细胞淋巴瘤免疫治疗的增强：代谢检查点抑制剂和免疫调节的协同潜力
Meghana K Rajendraprasad,John C Riches
Meghana K Rajendraprasad
For many patients with diffuse large B-cell lymphoma (DLBCL), frontline chemoimmunotherapy is curative; nonetheless, up to 40% of patients develop relapse or refractory disease. Immunotherapeutic approaches, such as immunomodulatory drugs, ...
Traditional Chinese Medicine in Cushing's Syndrome: A Narrative Review of Pathophysiology and Potential Therapeutic Effects [0.03%]
肾上腺皮质功能亢进症的中医研究——病理与潜在治疗作用综述
Baojiang Chen,Cong He,Lichao Han et al.
Baojiang Chen et al.
This article employs a narrative review approach to systematically elucidate the pathophysiological mechanisms of Cushing Syndrome (CS), with a particular focus on exploring the theoretical foundations, clinical applications, and future dir...
Tumor-Infiltrating Mast Cells Enhance Neoadjuvant Therapy Efficacy in ESCC via Modulation of the Desmoplastic Microenvironment [0.03%]
肿瘤浸润的肥大细胞通过调节粘膜下纤维化微环境增强食管鳞癌的新辅助治疗效果
Xing Cui,Xiangmei Zhang,Qi Zhao et al.
Xing Cui et al.
Objective: Neoadjuvant therapy is essential for locally advanced esophageal squamous cell carcinoma (ESCC), but its efficacy requires improvement. This study investigated the role of tumor-infiltrating mast cells (MCs) in...
The Robotic Interval Surgery, A Game-Changer in Optimal Debulking for Ovarian Cancer: A Systematic Review and Meta-Analysis [0.03%]
机器人间期手术在卵巢癌最优减瘤中的变革作用：系统评价和 meta 分析
Amanda Jessie Maharani,Pricillia Laurenza Salsabila,Najla Istyari Radina et al.
Amanda Jessie Maharani et al.
Purpose: This study evaluates the role of robotic-interval debulking surgery (robotic IDS) compared to traditional laparotomy as the game-changer in surgical outcome and complications for ovarian cancer patients. ...
HMGB1 as Double-Edged Regulator of Cancer Therapy: Mechanistic Roles in Chemotherapy Resistance and Immunotherapy Response [0.03%]
高迁移率族蛋白B1在癌症治疗中的双刃剑作用：其在化疗耐药和免疫治疗反应中的机制作用
Haoyuan Li,Bao Wen,Shuguang Bao et al.
Haoyuan Li et al.
High-mobility group box 1 (HMGB1) is a ubiquitous non-histone nuclear protein with multifaceted roles in cancer biology. Emerging evidence suggests that the biological effects of HMGB1 are highly context-dependent, being determined by its s...
Long-Term Survival in an Elderly HCV Patient with Double Primary Malignant Tumors Managed with Local Therapy Only [0.03%]
仅局部治疗老年患者双原发恶性肿瘤的长期生存案例（译文）
Bing-Yu Yang,Yi Zhou,Jian-Zhou Li et al.
Bing-Yu Yang et al.
Hepatitis C virus (HCV) infection is associated with both hepatic and extrahepatic malignancies. We report a 95-year-old male with chronic HCV infection who developed recurrent hepatocellular carcinoma (HCC) and subsequent splenic diffuse l...
Case Reports
OncoTargets and therapy. 2026 Mar 25:19:582880. DOI:10.2147/OTT.S582880 2026